Novartis NVS obtained FDA approval for onasemnogene abeparvovec-brve, a gene replacement therapy, for children two years and ...

The FDA has approved Itvisma (onasemnogene abeparvovec-brve) to treat children two years and older, teens, and adults living with spinal muscular atrophy (SMA). It is indicated for patients with a ...

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

The global solar inverter market was valued at US$12.81 billion in 2023 and is forecasted to reach US$24.40 billion by 2029, with a CAGR of 11.34% from 2024-2029. Solar inverters are crucial for ...

In light of geopolitical tensions and real purchasing power losses, precious metal prices are on the rise – and there is no ...

Investing.com -- Jefferies upgraded German solar inverter manufacturer SMA Solar to “buy” from “hold” and raised its price target to €39 from €22, citing improved profitability prospects driven by ...

There are many ways products can aid installation in the residential market, whether it’s software that makes designing easier or mounting systems with fewer parts to assemble. For the 2024 Top ...

Abstract: Conventional power electronic interfaces for multisource applications always need multiple conversion stages as intermediate dc–dc power conversion stages are inevitably installed for ...